Welcome to our dedicated page for Tandem Diabetes news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes stock.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is a global insulin delivery and diabetes technology company whose news flow centers on product innovation, regulatory milestones, financial performance, and corporate developments. The company manufactures and sells advanced automated insulin delivery systems, including the Tandem Mobi system and the t:slim X2 insulin pump, both featuring Control-IQ or Control-IQ+ hybrid closed-loop technology.
News updates for Tandem Diabetes Care often highlight regulatory and product announcements. Recent examples include FDA 510(k) clearance for the SteadiSet infusion set for up to seven days of use, FDA clearance for the Android version of the Tandem Mobi mobile app, and integration of the t:slim X2 pump with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring sensor in the United States. The company also issues press releases on software and mobile app availability, such as the Tandem t:slim mobile app launch for Android and iOS users in Canada.
Investors and observers can also expect regular earnings and guidance updates. Tandem Diabetes Care reports quarterly financial results and provides full-year guidance, with related press releases and conference call details disclosed publicly. Additional news items cover corporate governance, such as the appointment of new board members and committee assignments, as well as certifications like ISO/IEC 27001:2022 for information security.
This news page for TNDM aggregates these types of announcements, including earnings releases, regulatory clearances, product compatibility updates, conference presentations, and technology rollouts. It provides a single location to follow how Tandem Diabetes Care’s insulin delivery systems, digital platforms, and global initiatives are evolving over time.
Tandem Diabetes Care (Nasdaq: TNDM) has received FDA clearance for its Control-IQ+ automated insulin delivery technology for people with type 2 diabetes aged 18 and older. This next-generation algorithm, already approved for type 1 diabetes, includes enhancements to accommodate expanded weight and total daily insulin ranges.
The technology will be available for U.S. customers in March 2025. Control-IQ+ powers both the t:slim X2 and Tandem Mobi insulin delivery systems, which have shown significant clinical benefits in type 1 diabetes patients, including improved time in range and better sleep according to studies published in the New England Journal of Medicine.
The expanded indication is based on a pivotal trial involving over 300 people with type 2 diabetes, comparing the t:slim X2 pump with Control-IQ+ technology against multiple daily injections. Full study results will be presented at the International Conference on Advanced Technologies & Treatments for Diabetes in Amsterdam in March 2025.
Tandem Diabetes Care (TNDM), a leading insulin delivery and diabetes technology company, has announced its participation in four major healthcare investor conferences in March 2025:
• TD Cowen 45th Annual Health Care Conference - March 4, 2025, 1:50pm ET
• Barclays 27th Annual Global Healthcare Conference - March 11, 2025, 1:30pm ET
• Leerink Partners 2025 Global Healthcare Conference - March 12, 2025, 9:20am ET
• Oppenheimer 35th Annual Healthcare MedTech & Services Conference - March 20, 2025, 12:40pm ET
Management will present company updates at each conference. All presentations will be available via live webcast and archived for 30 days on Tandem's Investor Center website under the 'Events & Presentations' section.
Tandem Diabetes Care (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, has announced it will release its fourth quarter and full year 2024 financial results after market close on Wednesday, February 26, 2025.
The company will host a conference call and simultaneous webcast at 4:30 PM Eastern Time (1:30 PM Pacific Time) on the same day to discuss the financial and operating results. Investors can access the live webcast through Tandem's Investor Center website. A recording of the webcast will be available for 30 days following the event in the "Events & Presentations" section.
Tandem Diabetes Care (TNDM) has announced a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology (UVA) to advance research and development of fully automated closed-loop insulin delivery systems. The partnership builds on their previous successful collaboration in the International Diabetes Closed Loop trials.
The collaboration combines UVA's expertise in technology-based interventions and automated insulin delivery (AID) algorithms with Tandem's market leadership in insulin delivery devices, algorithm implementation, and data management. The research will involve scientists, clinicians, and experts from both institutions, potentially leading to clinical research for Tandem's next-generation AID systems.
As part of the agreement, Tandem will provide research funding, technology, and supplies to UVA for diabetes-centered research and potential clinical studies.
Tandem Diabetes Care and Dexcom announced that Health Canada has authorized the sale of the t:slim X2™ insulin pump with full compatibility for both Dexcom G6 and G7 Continuous Glucose Monitoring (CGM) Systems. This makes the t:slim X2 the first insulin pump in Canada integrated with both CGMs. The t:slim X2, which features Control-IQ technology, is highly rated and now offers Canadian users more options for diabetes management.
The integration launched in the U.S. in December 2023, and now Canadian users can benefit from the faster 30-minute sensor warm-up time of the Dexcom G7 and the ability to view glucose levels on an Apple smartwatch. Tandem will provide the new compatibility feature free of charge via a remote software update to in-warranty users and will begin shipping updated pumps in early January 2025. For more information, users can visit tandemdiabetes.ca or dexcom.com.
Tandem Diabetes Care (NASDAQ: TNDM) has announced its participation in two upcoming investor conferences. The company will present updates at the 36th Annual Piper Sandler Healthcare Conference on December 3, 2024, at 8:00am ET, and at Citi's 2024 Global Healthcare Conference on December 4, 2024, at 1:00pm ET. Both presentations will be available via live webcast and archived for 30 days on Tandem's Investor Center website under the Events & Presentations section.
Tandem Diabetes Care (TNDM) reported strong Q3 2024 financial results with worldwide GAAP sales increasing 31% to $244.0 million. The company achieved its highest quarterly sales in history, both domestically and internationally. Worldwide pump shipments grew by over 25% compared to Q3 2023, with approximately 21,000 pumps shipped in the US and nearly 11,000 internationally. The company demonstrated positive Adjusted EBITDA of $4.0 million (2% of sales) and returned to positive free cash flow. Despite these improvements, TNDM still reported a GAAP net loss of $23.3 million, though this was an improvement from the $33.0 million loss in Q3 2023.
Tandem Diabetes Care (TNDM) has announced its participation in multiple investor conferences in November 2024. The company will present updates at the UBS Global Healthcare Conference (Nov 14), Stifel Healthcare Conference (Nov 19), Jefferies London Healthcare Conference (Nov 20), and Wolfe Research Healthcare Conference (Nov 20). Additionally, they will host meetings at the Canaccord Genuity MedTech Forum (Nov 21). All presentations will be webcast live with 30-day archive access through Tandem's Investor Center website.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, has announced plans to release its third quarter 2024 financial results on Wednesday, November 6, 2024, after the financial markets close. The company will host a conference call and simultaneous webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) on the same day to discuss the results.
Investors and interested parties can access the live webcast of the call through Tandem Diabetes Care's Investor Center website. For those wishing to join by phone, a registration link is provided to obtain dial-in details and a personal pin. An archive of the webcast will be available for 30 days following the event on the company's Investor Center website.
Tandem Diabetes Care (NASDAQ: TNDM) has announced that its t:slim X2 insulin pump with Control-IQ automated insulin delivery technology is now compatible with Eli Lilly's Lyumjev ultra-rapid acting insulin in the European Union. This compatibility offers more flexibility for diabetes patients using Tandem's AID system in the EU.
A recent clinical study demonstrated high satisfaction and quality of life benefits when using Lyumjev with Control-IQ technology. Tandem and Lilly collaborated on this study and are working to secure Lyumjev compatibility for the t:slim X2 pump in other regions and for the Tandem Mobi pump.